Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
Price:
24.85 CNY
-0.84%
Market Closed
Updated:
May 17, 2024
P/E
Price to Earnings
Price to Earnings
26.4
Current
17.6
Median
23.5
Industry
Higher
than median
Higher
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=26.4
Market Cap
/
13.9B
Net Income
526.2m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| CN |
|
Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
|
13.9B CNY | 26.4 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 347 888.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
731.8B USD | 119.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 45.1 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | -15 783.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
372.2B USD | 9.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
332.3B USD | 144.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.7B GBP | 37.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
189B CHF | 16.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.7B CHF | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161.3B USD | -522.1 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
26
2-Years Forward
P/E
21.2
3-Years Forward
P/E
18.1
You don't have any saved screeners yet
